Obesity & Diabetes Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity & Diabetes Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
GI Dynamics
GI Dynamics' EndoBarrier(TM) Gastrointestinal Liner Demonstrates Safety and Efficacy in Pre-surgical Weight Loss
November 9th, 2009
GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, announced data which support the safety and efficacy of the EndoBarrier™ Gastrointestinal Liner for pre-surgical weight loss treatment, along with a positive effect on glucose homeostasis in morbidly obese patients with type 2 diabetes mellitus. According to the study, mean excess weight loss (EWL) achieved after 12 weeks post implantation was 19.0 % for EndoBarrier patients versus 6.9 % for control patients (p<0.002). The results of this European weight loss study were published in the advance online publication of Annals of Surgery. "As worldwide incidence of...
Source: Obesity & Diabetes Week (2009-11-09)
|
